Cargando…

The TAM family as a therapeutic target in combination with radiation therapy

Radiation therapy is primarily a modality to kill cancer cells in the treatment field. It is becoming increasingly clear that radiation therapy can also be used to direct immune responses that have the potential to clear residual local or distant disease outside the treatment field. We believe that...

Descripción completa

Detalles Bibliográficos
Autores principales: Tormoen, Garth W., Crittenden, Marka R., Gough, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093058/
https://www.ncbi.nlm.nih.gov/pubmed/32211517
http://dx.doi.org/10.1042/ETLS20170066
_version_ 1783510224798220288
author Tormoen, Garth W.
Crittenden, Marka R.
Gough, Michael J.
author_facet Tormoen, Garth W.
Crittenden, Marka R.
Gough, Michael J.
author_sort Tormoen, Garth W.
collection PubMed
description Radiation therapy is primarily a modality to kill cancer cells in the treatment field. It is becoming increasingly clear that radiation therapy can also be used to direct immune responses that have the potential to clear residual local or distant disease outside the treatment field. We believe that cancer cell death is the critical link between these processes. Understanding the handling of dying cancer cells by immune cells in the tumor environment is crucial to facilitate immune responses following radiation therapy. We review the role of the TAM (Tyro3 Axl Mertk) group of receptor tyrosine kinases and their role following radiation-induced cancer cell death in the tumor environment.
format Online
Article
Text
id pubmed-7093058
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-70930582020-03-24 The TAM family as a therapeutic target in combination with radiation therapy Tormoen, Garth W. Crittenden, Marka R. Gough, Michael J. Emerg Top Life Sci Review Articles Radiation therapy is primarily a modality to kill cancer cells in the treatment field. It is becoming increasingly clear that radiation therapy can also be used to direct immune responses that have the potential to clear residual local or distant disease outside the treatment field. We believe that cancer cell death is the critical link between these processes. Understanding the handling of dying cancer cells by immune cells in the tumor environment is crucial to facilitate immune responses following radiation therapy. We review the role of the TAM (Tyro3 Axl Mertk) group of receptor tyrosine kinases and their role following radiation-induced cancer cell death in the tumor environment. Portland Press Ltd. 2017-12-15 2017-12-12 /pmc/articles/PMC7093058/ /pubmed/32211517 http://dx.doi.org/10.1042/ETLS20170066 Text en © 2017 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Articles
Tormoen, Garth W.
Crittenden, Marka R.
Gough, Michael J.
The TAM family as a therapeutic target in combination with radiation therapy
title The TAM family as a therapeutic target in combination with radiation therapy
title_full The TAM family as a therapeutic target in combination with radiation therapy
title_fullStr The TAM family as a therapeutic target in combination with radiation therapy
title_full_unstemmed The TAM family as a therapeutic target in combination with radiation therapy
title_short The TAM family as a therapeutic target in combination with radiation therapy
title_sort tam family as a therapeutic target in combination with radiation therapy
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093058/
https://www.ncbi.nlm.nih.gov/pubmed/32211517
http://dx.doi.org/10.1042/ETLS20170066
work_keys_str_mv AT tormoengarthw thetamfamilyasatherapeutictargetincombinationwithradiationtherapy
AT crittendenmarkar thetamfamilyasatherapeutictargetincombinationwithradiationtherapy
AT goughmichaelj thetamfamilyasatherapeutictargetincombinationwithradiationtherapy
AT tormoengarthw tamfamilyasatherapeutictargetincombinationwithradiationtherapy
AT crittendenmarkar tamfamilyasatherapeutictargetincombinationwithradiationtherapy
AT goughmichaelj tamfamilyasatherapeutictargetincombinationwithradiationtherapy